Skip to main content

Table 4 Adverse events

From: Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Adverse events

Grade 1-2

Grade 3-4

Alopecia

89.3% (25/28)

 

Leucopenia

25.0% (7/28)

10.7% (3/28)

Fatigue

21.4% (6/28)

3.6% (1/28)

Anemia

21.4% (6/28)

 

Nausea

21.4% (6/28)

3.6% (1/28)

Peripheral neuropathy

17.9% (5/28)

10.7% (3/28)

Transaminase increase

17.9% (5/28)

7.1% (2/28)

Anorexia

14.3% (4/28)

3.6% (1/28)

Diarrhea

14.3% (4/28)

3.6% (1/28)

Thrombocytopenia

14.3% (4/28)

 

Hypothyroidism

14.3% (4/28)

3.6% (1/28)

Pneumonitis

10.7% (3/28)

3.6% (1/28)

Fever

10.7% (3/28)

 

Abdominal pain

7.1% (2/28)

 

Rash

3.6% (1/28)

 
  1. Data are presented as percentages (number events/total). Adverse events were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)